Trial Profile
A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms TAPER
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 06 Feb 2024 This trial has been completed in Italy, according to European Clinical Trials Database record
- 01 Jan 2024 Results of 12-month TAPER primary analysis and follow-up analysis published in the American Journal of Hematology
- 03 Nov 2022 Status changed from active, no longer recruiting to completed.